Our top pick for
Veru Inc is a biotechnology business based in the US. Veru shares (VERU) are listed on the NASDAQ and all prices are listed in US Dollars. Veru employs 339 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.09|
|52-week range||$2.30 - $24.57|
|50-day moving average||$8.72|
|200-day moving average||$8.32|
|Wall St. target price||$24.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.00|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-4.26%|
|1 month (2021-09-24)||-10.80%|
|3 months (2021-07-26)||16.74%|
|6 months (2021-04-26)||-14.21%|
|1 year (2020-10-26)||230.20%|
|2 years (2019-10-25)||304.50%|
|3 years (2018-10-26)||532.03%|
|5 years (2016-10-26)||700.99%|
Valuing Veru stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veru's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Veru's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 million.
The EBITDA is a measure of a Veru's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$57.4 million|
|Gross profit TTM||$30.8 million|
|Return on assets TTM||-0.38%|
|Return on equity TTM||-0.15%|
|Market capitalisation||$646 million|
TTM: trailing 12 months
There are currently 2.6 million Veru shares held short by investors – that's known as Veru's "short interest". This figure is 3.9% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting Veru shares can be evaluated.
Veru's "short interest ratio" (SIR) is the quantity of Veru shares currently shorted divided by the average quantity of Veru shares traded daily (recently around 929705.30035336). Veru's SIR currently stands at 2.83. In other words for every 100,000 Veru shares traded daily on the market, roughly 2830 shares are currently held short.
However Veru's short interest can also be evaluated against the total number of Veru shares, or, against the total number of tradable Veru shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veru's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Veru shares in existence, roughly 30 shares are currently held short) or 0.041% of the tradable shares (for every 100,000 tradable Veru shares, roughly 41 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Veru.
Find out more about how you can short Veru stock.
We're not expecting Veru to pay a dividend over the next 12 months.
Over the last 12 months, Veru's shares have ranged in value from as little as $2.3 up to $24.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veru's is 0.6407. This would suggest that Veru's shares are less volatile than average (for this exchange).
Veru Inc. , an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U. N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.